GDB’s patent application claiming the combination of GLP-1 RA and SGLT2i was published in China.

GDB ispleased to announce that the patent application claiming the combination ofGLP-1 RA and SGLT2i (International Application Number PCT/CN2021/142542) enterinto the publication status in China. The publication date is October 1, 2024.This is the patent application to protect the innovative oral formulation ofcombining macromolecule GLP-1 receptor agonist peptide and small molecule SGLT2inhibitor. The application will enter into the national phase of China, US, EU,and Japan et. al. under the PCT pathway.